Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

2 weeks ago 9

Jeff Lewis

Sat, April 4, 2026 astatine 7:17 AM CDT 2 min read

Ascendis Pharma A/S (NASDAQ:ASND) is 1 of the

7 Fastest Growing European Stocks to Invest In. On March 17, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced affirmative Week 52 topline results from the Phase 2 New InsiGHTS proceedings evaluating once-weekly TransCon hGH against regular somatropin successful prepubertal children with Turner syndrome. At Week 52, annualized tallness velocity was akin betwixt the 2 groups, with an LS mean of 9.05 cm/year for TransCon hGH-treated children versus 9.04 cm/year for regular somatropin. The institution besides said TransCon hGH showed a information and tolerability illustration akin to regular somatropin done follow-up of up to 143 weeks, with adverse events reported arsenic mild to mean and nary discontinuations owed to adverse events.

On March 16, 2026, Jefferies assumed sum of Ascendis Pharma A/S (NASDAQ:ASND) with a Buy standing and a $290 terms target, describing the institution arsenic a “two-engine maturation story” with Yorvipath connected a “hot maturation trajectory” and Yuviwel positioned to “disrupt” achondroplasia successful the adjacent term.

Ascendis Pharma A/S (ASND) Reports Positive Week 52 Data from Phase 2 New InsiGHTS Trial

A aesculapian technician holding the instruments successful her hands

On the aforesaid day, the institution announced caller information from its pivotal ApproaCH proceedings showing that children with achondroplasia treated with once-weekly TransCon CNP maintained maturation improvements done Week 104, with further gains successful assemblage proportionality during the 2nd twelvemonth of treatment. Ascendis said TransCon CNP, approved by the U.S. FDA successful February 2026 nether the commercialized sanction YUVIWEL, remains nether reappraisal by the European Medicines Agency, with a determination expected successful the 4th fourth of 2026.

Ascendis Pharma A/S (NASDAQ:ASND) develops TransCon-based therapies for unmet aesculapian needs.

While we admit the imaginable of ASND arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article